By Fineline Cube 
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced last month a strategic partnership with US generic company Somerset Therapeutics LLC to accelerate its business expansion in the US. This collaboration builds on a supply and distribution agreement signed in May of this year.
Partnership Agreement
Under the agreement, Zhaoke will develop ophthalmic drugs tailored for the US market. Somerset Therapeutics has been granted exclusive regulatory filing rights in the region. Zhaoke will be responsible for manufacturing and supplying the products to Somerset for commercialization upon regulatory approval.
Commercialization Strategy
The partnership leverages Zhaoke’s expertise in ophthalmic drug development and Somerset’s regulatory and commercial capabilities in the US. This strategic alliance aims to streamline the regulatory approval process and expedite the commercialization of ophthalmic therapies, addressing unmet medical needs in the US market.-Fineline Info & Tech